Trial Profile
The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 02 Jun 2017 New trial record